| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC0472 |
| Trial ID | NCT03870945 |
| Disease | B-Cell Non-Hodgkin's Lymphoma |
| Altered gene | CD19|CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Zamtocabtagene Autoleucel|MB-CART2019.1 |
| Phase | Phase1|Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) |
| Year | 2019 |
| Country | Germany |
| Company sponsor | Miltenyi Biomedicine GmbH |
| Other ID(s) | M-2018-331 |
| Vector information | |||
|
|||
| Cohort1: dose level 1 | |||||||||||||||||
|
|||||||||||||||||
| Cohort2: dose level 2 | |||||||||||||||||
|
|||||||||||||||||